Institutional Investors Are Dumping Medicinova Inc (NASDAQ:MNOV)

September 16, 2018 - By Kyle Williams

Sentiment for Medicinova Inc (NASDAQ:MNOV)

Medicinova Inc (NASDAQ:MNOV) institutional sentiment decreased to 1.04 in 2018 Q2. Its down -1.25, from 2.29 in 2018Q1. The ratio has dropped, as 24 investment managers started new or increased positions, while 23 cut down and sold equity positions in Medicinova Inc. The investment managers in our partner’s database now own: 8.79 million shares, down from 9.25 million shares in 2018Q1. Also, the number of investment managers holding Medicinova Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 17 Increased: 17 New Position: 7.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company has market cap of $477.42 million. The companyÂ’s product candidate includes MN-166 , an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. It currently has negative earnings. The Company’s product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers.

The stock decreased 0.52% or $0.06 during the last trading session, reaching $11.4. About 45,707 shares traded. MediciNova, Inc. (NASDAQ:MNOV) has risen 107.61% since September 16, 2017 and is uptrending. It has outperformed by 91.99% the S&P500.

Wexford Capital Lp holds 0.06% of its portfolio in MediciNova, Inc. for 125,000 shares. Bridgeway Capital Management Inc owns 97,710 shares or 0.01% of their US portfolio. Moreover, Highland Capital Management Lp has 0.01% invested in the company for 16,272 shares. The Colorado-based Alps Advisors Inc has invested 0% in the stock. American Century Companies Inc, a Missouri-based fund reported 71,288 shares.

MediciNova, Inc. (NASDAQ:MNOV) Ratings Coverage

Ratings analysis reveals 100% of Medicinova’s analysts are positive. Out of 2 Wall Street analysts rating Medicinova, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $22 while the high is $2200. The stock’s average target of $22 is 92.98% above today’s ($11.4) share price. MNOV was included in 2 notes of analysts from March 28, 2018. The firm earned “Buy” rating on Wednesday, March 28 by FBR Capital.

More recent MediciNova, Inc. (NASDAQ:MNOV) news were published by: Nasdaq.com which released: “National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of …” on August 20, 2018. Also Nasdaq.com published the news titled: “Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes …” on August 20, 2018. Seekingalpha.com‘s news article titled: “MediNova up 9% after hours on successful mid-stage study of ibudilast in MS” with publication date: August 30, 2018 was also an interesting one.

MediciNova, Inc. (NASDAQ:MNOV) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.